XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Our disaggregated revenues were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Royalties$155,061 $114,433 $400,572 $325,813 
Product sales, net
Proprietary product sales
39,925 31,511 119,319 91,765 
Bulk rHuPH20 sales
31,493 37,001 66,637 86,203 
Device partnered product sales
15,241 18,057 38,172 43,284 
Total product sales, net86,659 86,569 224,128 221,252 
Revenues under collaborative agreements
  Upfront license and target nomination fees27,000 — 27,000 — 
Event-based development and regulatory milestones and other fees
18,000 13,000 57,500 46,000 
Device licensing and development revenue
3,364 2,031 8,116 6,149 
Total revenues under collaborative agreements48,364 15,031 92,616 52,149 
Total revenues$290,084 $216,033 $717,316 $599,214 
During the three months ended September 30, 2024, we recognized revenue related to licenses granted to partners in prior periods in the amount of $173.1 million. This amount represents royalties earned in the current period in addition to $18.0 million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. Revenue recognized during the three months ended September 30, 2024 that had been included in accrued expense and other long-term liabilities in our condensed consolidated balance sheets as of December 31, 2023 was not material.
During the nine months ended September 30, 2024, we recognized revenue related to licenses granted to partners in prior periods in the amount of $458.1 million. This amount represents royalties earned in the current period in addition to $57.5 million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $0.6 million during the nine months ended September 30, 2024 that had been included in accrued expense and other long-term liabilities in our condensed consolidated balance sheets as of December 31, 2023.
Accounts receivable, net, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands):
September 30, 2024December 31, 2023
Accounts receivable, net$273,062 $233,254 
Other contract assets12,681 956 
Deferred revenues9,126 4,048 
As of September 30, 2024, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $88.3 million, of which $79.2 million relates to unfulfilled product purchase orders and $9.1 million has been collected and is reported as accrued expense and other long-term liabilities in our condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2025. Of the total deferred revenues of $9.1 million, $0.8 million is expected to be used by our customers within the next 12 months.
We recognized contract assets of $12.7 million as of September 30, 2024, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.